Healthcare provider profile · identity verified

Jerald B. Feinland, MD

Family Practice · EASTHAMPTON, MA · NPI 1114986460

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	263	68
Hydrochlorothiazide	Hydrochlorothiazide	230	54
Amlodipine Besylate	Amlodipine Besylate	199	59
Gabapentin	Gabapentin	197	35
Oxycodone Hcl	Oxycodone Hcl	184	30
Atorvastatin Calcium	Atorvastatin Calcium	155	43
Metoprolol Succinate	Metoprolol Succinate	139	38
Levothyroxine Sodium	Levothyroxine Sodium	128	32
Albuterol Sulfate Hfa	Albuterol Sulfate	115	32
Metformin Hcl	Metformin Hcl	112	22
Omeprazole	Omeprazole	110	30
Trazodone Hcl	Trazodone Hcl	102	26
Morphine Sulfate Er	Morphine Sulfate	90	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	85	suppressed
Losartan Potassium	Losartan Potassium	82	19
Olmesartan Medoxomil	Olmesartan Medoxomil	76	24
Clonazepam	Clonazepam	70	11
Simvastatin	Simvastatin	66	12
Sertraline Hcl	Sertraline Hcl	65	19
Allopurinol	Allopurinol	58	17
Methadone Hcl	Methadone Hcl	57	suppressed
Furosemide	Furosemide	56	16
Tamsulosin Hcl	Tamsulosin Hcl	56	17
Bupropion Xl	Bupropion Hcl	54	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	53	20
Lorazepam	Lorazepam	52	12
Potassium Chloride	Potassium Chloride	51	13
Pravastatin Sodium	Pravastatin Sodium	46	12
Spironolactone	Spironolactone	44	suppressed
Prednisone	Prednisone	43	26
Eliquis	Apixaban	38	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	38	suppressed
Trulicity	Dulaglutide	38	suppressed
Fluticasone Propionate	Fluticasone Propionate	37	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	37	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	36	11
Xarelto	Rivaroxaban	36	suppressed
Alprazolam	Alprazolam	35	suppressed
Famotidine	Famotidine	33	11
Ozempic	Semaglutide	33	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	32	suppressed
Metformin Hcl Er	Metformin Hcl	31	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	29	suppressed
Finasteride	Finasteride	28	suppressed
Verapamil Er	Verapamil Hcl	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	27	suppressed
Warfarin Sodium	Warfarin Sodium	27	suppressed
Carvedilol	Carvedilol	26	suppressed
Terazosin Hcl	Terazosin Hcl	25	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	24	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	24	19
Lamotrigine	Lamotrigine	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Aripiprazole	Aripiprazole	22	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	22	suppressed
Meloxicam	Meloxicam	22	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	22	suppressed
Atenolol	Atenolol	21	suppressed
Ipratropium Bromide	Ipratropium Bromide	21	suppressed
Mirtazapine	Mirtazapine	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Glipizide	Glipizide	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Naloxone Hcl	Naloxone Hcl	20	14
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Naproxen	Naproxen	19	suppressed
Torsemide	Torsemide	19	suppressed
Baclofen	Baclofen	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Montelukast Sodium	Montelukast Sodium	17	suppressed
Mounjaro	Tirzepatide	17	suppressed
Propranolol Hcl Er	Propranolol Hcl	17	suppressed
Tramadol Hcl	Tramadol Hcl	17	11
Triamcinolone Acetonide	Triamcinolone Acetonide	17	14
Arnuity Ellipta	Fluticasone Furoate	16	suppressed
Celecoxib	Celecoxib	16	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	12
Dulera	Mometasone/Formoterol	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Diazepam	Diazepam	14	suppressed
Jantoven	Warfarin Sodium	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Temazepam	Temazepam	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Fentanyl	Fentanyl	13	suppressed
Gemtesa	Vibegron	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Guanfacine Hcl	Guanfacine Hcl	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Topiramate	Topiramate	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Dextroamphetamine Sulfate Er	Dextroamphetamine Sulfate	11	suppressed
Minocycline Hcl	Minocycline Hcl	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error